CompletedPhase 2NCT02019693
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Studying Hereditary clear cell renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ramaprasad Srinivasan, M.D.National Cancer Institute (NCI)
- Intervention
- INC280(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2021
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02019693 on ClinicalTrials.govOther trials for Hereditary clear cell renal cell carcinoma
Additional recruiting or active studies for the same condition.
See all trials for Hereditary clear cell renal cell carcinoma →